These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35440669)

  • 1. Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.
    Umeh-Garcia M; O'Geen H; Simion C; Gephart MH; Segal DJ; Sweeney CA
    Br J Cancer; 2022 Aug; 127(3):436-448. PubMed ID: 35440669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
    Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
    Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.
    Bagu ET; Miah S; Dai C; Spriggs T; Ogunbolude Y; Beaton E; Sanders M; Goel RK; Bonham K; Lukong KE
    Oncotarget; 2017 Feb; 8(7):11442-11459. PubMed ID: 28077797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer.
    Good CR; Panjarian S; Kelly AD; Madzo J; Patel B; Jelinek J; Issa JJ
    Cancer Res; 2018 Aug; 78(15):4126-4137. PubMed ID: 29891505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TET1 Depletion Induces Aberrant CpG Methylation in Colorectal Cancer Cells.
    Kai M; Niinuma T; Kitajima H; Yamamoto E; Harada T; Aoki H; Maruyama R; Toyota M; Sasaki Y; Sugai T; Tokino T; Nakase H; Suzuki H
    PLoS One; 2016; 11(12):e0168281. PubMed ID: 27977763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter.
    Choudhury SR; Cui Y; Lubecka K; Stefanska B; Irudayaraj J
    Oncotarget; 2016 Jul; 7(29):46545-46556. PubMed ID: 27356740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
    Mossman D; Kim KT; Scott RJ
    BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
    Ramezani F; Salami S; Omrani MD; Maleki D
    Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
    Pulukuri SM; Rao JS
    Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
    Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
    Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
    Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
    Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.
    Barrio-Real L; Benedetti LG; Engel N; Tu Y; Cho S; Sukumar S; Kazanietz MG
    Breast Cancer Res; 2014 Sep; 16(5):441. PubMed ID: 25248717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The frequency of CpG and non-CpG methylation of Notch3 gene promoter determines its expression levels in breast cancer cells.
    Xiao W; Liu X; Niu X; Li C; Guo Y; Tan J; Xiong W; Fan L; Li Y
    Exp Cell Res; 2020 Jan; 386(2):111743. PubMed ID: 31770532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.
    Augoff K; McCue B; Plow EF; Sossey-Alaoui K
    Mol Cancer; 2012 Jan; 11():5. PubMed ID: 22289355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.
    Kulak MV; Cyr AR; Woodfield GW; Bogachek M; Spanheimer PM; Li T; Price DH; Domann FE; Weigel RJ
    Oncogene; 2013 Aug; 32(34):4043-51. PubMed ID: 22964634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation-dependent silencing of CST6 in human breast cancer cell lines.
    Rivenbark AG; Jones WD; Coleman WB
    Lab Invest; 2006 Dec; 86(12):1233-42. PubMed ID: 17043665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer.
    Liu M; Peng Y; Wang X; Guo Q; Shen S; Li G
    BMC Cancer; 2010 Apr; 10():160. PubMed ID: 20423473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Putative promoters within gene bodies control exon expression via TET1-mediated H3K36 methylation.
    Ma L; Muhammad T; Wang H; Du G; Sakhawat A; Wei Y; Ali Khan A; Cong X; Huang Y
    J Cell Physiol; 2020 Oct; 235(10):6711-6724. PubMed ID: 31994732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.
    Yokdang N; Hatakeyama J; Wald JH; Simion C; Tellez JD; Chang DZ; Swamynathan MM; Chen M; Murphy WJ; Carraway Iii KL; Sweeney C
    Oncogene; 2016 Jun; 35(22):2932-47. PubMed ID: 26387542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.